Israel

AI Citation Summary

• Country: Israel
• Product line: Medical devices
• Regulator / source: Market Characteristics: A high-technology medical market with high per capita healthcare expenditure; a significant proportion of private hospitals and outpatient clinics; strong demand for innovative medical devices; a well-developed domestic medical technology industry (numerous startups and multinational R&D centers); regulatory quality aligned with Europe and the United States
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
• Key fees: Regulatory route - Which product category, risk class, application type, reliance route, or special pathway applies? - Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
• Local requirement: Israel medical-device entry should be separated into Israel Ministry of Health AMAR regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 9.5 million (2024)
• Healthcare System: Universal mandatory health insurance (the Kupot Holim system — four major health funds: Clalit, Maccabi, Meuhedet, Leumit), with coexisting public and private sectors and extremely high coverage rates
• Market Characteristics: A high-technology medical market with high per capita healthcare expenditure; a significant proportion of private hospitals and outpatient clinics; strong demand for innovative medical devices; a well-developed domestic medical technology industry (numerous startups and multinational R&D centers); regulatory quality aligned with Europe and the United States
• Regulatory Maturity: Highly mature; the regulatory framework is benchmarked against EU MDR; broadly recognizes FDA 510(k)/PMA and EU CE marking as reference market approvals

Market-Entry Logic

Israel medical-device entry should be separated into Israel Ministry of Health AMAR regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Entry layer	Key question	Practical view
Regulatory route	Which product category, risk class, application type, reliance route, or special pathway applies?	Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
Local execution	Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations?	Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product
Evidence and economics	What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed?	Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption
Channel access	Which payer, hospital, distributor, retail, tender, or private-care channel will create volume?	Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type	Representative players	Market meaning
Regulator / review	Israel Ministry of Health AMAR	Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment / procurement	health funds / HMOs, Ministry of Health basket committee, hospitals and private insurers	Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies / channels	Medtronic, Philips, GE HealthCare, Siemens Healthineers, local startups, Sheba, Hadassah, Ichilov and HMO procurement channels	Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users / buyers	Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors	Determine adoption, tender volume, reference cases, service expectations, and receivables risk

Development Trends

1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
4. Pricing pressure is structural: reference-country reliance, health basket access, strong digital-health ecosystem, HMO purchasing power, security logistics and startup partnership opportunities are reshaping launch sequencing and product economics.
5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authority

• Competent Authority: Ministry of Health of Israel (MOH / משרד הבריאות), through the Medical Technology, Cosmetics and Non-Ionizing Radiation Division (MTCNIR); specific registration matters are handled by AMAR (Agaf Meizug Rishum / אגף מאיזון רישום — the Medical Device Registration Directorate)
• Official Portal: https://www.health.gov.il/English/Topics/MedicalEquipment/Pages/default.aspx (English); AMAR online submission system: https://amar.health.gov.il
• Key Regulations:
  • Medical Devices Law 5772-2012
  • Medical Devices Regulations 5774-2014
  • MOH Circulars / Director General Circulars: continuously updated technical requirements
  • IVDs are separately regulated under the In Vitro Diagnostic Devices Regulations

Device Classification System

Local Class	Risk Level	EU/FDA Equivalent	Description
Class 1	Low risk	EU Class I / FDA Class I	General devices; some exempt from registration
Class 2	Low-medium risk	EU Class IIa / FDA Class II	Registration required; eligible for reference market fast-track pathway
Class 3	Medium-high risk	EU Class IIb / FDA Class II–III	Full technical review required; may leverage reference market approvals
Class 4	High risk	EU Class III / FDA Class III (PMA)	Highest review level; strong clinical evidence required

IVDs have an independent classification system, divided into Classes A/B/C/D following the EU IVDR framework.

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.